Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact of the Double Expression of MYC and BCL2 on Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma Following R-CHOP Chemoimmunotherapy

Tomotaka Suzuki, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Kinuko Tajima, Yuta Ito, MD, Shunsuke Hatta, MD PhD, Sayako Yuda, MD, PhD, Shinichi Makita, MD, PhD, Suguru Fukuhara, MD, Wataru Munakata, MD PhD, Tatsuya Suzuki, MD, PhD, Hirokazu Taniguchi, MD, Yukio Kobayashi, MD PhD, Koji Izutsu, MD, PhD, Kensei Tobinai, MD PhD

Blood (2017) 130 (Supplement 1): 2846.

https://doi.org/10.1182/blood.V130.Suppl_1.2846.2846

Published: 2017

Journal Articles

Secondary Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Yosuke Tanaka, MD, Saiko Kurosawa, MD, Kinuko Tajima, Yoshihiro Inamoto, MD PhD, Reiko Ito, MD, Takashi Tanaka, MD, Yoshitaka Inoue, MD, Takayuki Ozawa, MD, Akihisa Kawajiri, MD, Akio Onishi, MD, Keiji Okinaka, MD, Shigeo Fuji, MD, Sung-Won Kim, MD, Ryuji Tanosaki, MD PhD, Takuya Yamashita, MD PhD, Takahiro Fukuda, MD

Blood (2015) 126 (23): 3162.

https://doi.org/10.1182/blood.V126.23.3162.3162

Published: 2015

Journal Articles

Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era

Sayako Yuda, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Miyamoto Ken-ichi, MD, Suguru Fukuhara, MD, Wataru Munakata, MD, Tatsuya Suzuki, MD PhD, Yukio Kobayashi, MD PhD, Kinuko Tajima, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 4475.

https://doi.org/10.1182/blood.V124.21.4475.4475

Published: 2014

Journal Articles

The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy

Akihisa Kawajiri, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Ken-ichi Miyamoto, MD, Suguru Fukuhara, MD, Tatsuya Suzuki, MD PhD, Wataru Munakata, MD, Yukio Kobayashi, Kinuko Tajima, Jun Itami, MD PhD, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 1761.

https://doi.org/10.1182/blood.V124.21.1761.1761

Published: 2014

Journal Articles

Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile

Blood (2014) 124 (21): 1221.

https://doi.org/10.1182/blood.V124.21.1221.1221

Published: 2014

Journal Articles

High Non-Relapse Mortality and Low Relapse Incidence in Sex-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation From Female Donor with Male Child

Akihito Shinohara, M.D., Ph.D., Nobuhiro Hiramoto, MD, Saiko Kurosawa, M.D., Ryosuke Ueda, MD, Takashi Tanaka, MD, Kohei Tada, MD, Yujin Kobayashi, MD, Noriyuki Morikawa, MD, Keiji Okinaka, MD, Kinuko Tajima, Takuya Yamashita, M.D., Ph.D., Mineo Kurokawa, M.D., Takahiro Fukuda, MD, PhD

Blood (2012) 120 (21): 1945.

https://doi.org/10.1182/blood.V120.21.1945.1945

Published: 2012

Journal Articles

Alloimmune Effect May Improve Survival of De Novo Myelodysplastic Syndrome After allogeneic hematopoietic cell transplantaion: A Single Center Analysis of 115 Patients

Nobuhiro Hiramoto, MD, Kinuko Tajima, Saiko Kurosawa, MD, Takuya Yamashita, MD, Kenji Okinaka, MD, Noriyuki Morikawa, MD, Kohei Tada, MD, Takashi Tanaka, MD, Ryosuke Ueda, MD, Yujin Kobayashi, MD, Akihito Shinohara, MD, Sung-Won Kim, MD, Shin-ichiro Mori, MD, Yuji Heike, MD, Takahiro Fukuda, MD

Blood (2011) 118 (21): 2033.

https://doi.org/10.1182/blood.V118.21.2033.2033

Published: 2011

Journal Articles

Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC) for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan

Sung-Won Kim, MD, Takahiro Fukuda, MD, Shotaro Hagiwara, MD, Tsunehiko Komatsu, MD, Tetsuya Goto, MD, Yasunori Ueda, M.D., Toshiro Ito, MD, Masayuki Hino, MD, Kazutaka Sunami, MD, Ryuji Tanosaki, MD, Shin-ichiro Mori, MD, Masahiro Kami, MD, Kinuko Tajima, Yoichi Takaue, MD

Blood (2008) 112 (11): 1170.

https://doi.org/10.1182/blood.V112.11.1170.1170

Published: 2008

Journal Articles

Impact of T-Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen.

Bungo Saito, MD, Takahiro Fukuda, MD, Hiroki Yokoyama, MD, Saiko Kurosawa, MD, Toshihiro Takahashi, MD, Shigeo Fuji, MD, Noriko Takahashi, Kinuko Tajima, PhD, Sung-Won Kim, MD, Shin-ichiro Mori, MD, Ryuji Tanosaki, MD, Yoichi Takaue, MD, Yuji Heike, MD

Blood (2007) 110 (11): 2009.

https://doi.org/10.1182/blood.V110.11.2009.2009

Published: 2007

Journal Articles

Effect of Interventions for Relapse or Progression Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience of 93 Patients.

Saiko Kurosawa, MD, Takahiro Fukuda, MD, Shin-ichiro Mori, MD, Sung-Won Kim, MD, Shigeo Fuji, MD, Bungo Saito, MD, Toshihiro Takahashi, MD, Hiroki Yokoyama, MD, Kinuko Tajima, Ryuji Tanosaki, MD, Kensei Tobinai, MD, Yoichi Takaue, MD

Blood (2007) 110 (11): 1648.

https://doi.org/10.1182/blood.V110.11.1648.1648

Published: 2007

Journal Articles

Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients.

Hiroki Yokoyama, MD, Takahiro Fukuda, MD, Yukio Kobayashi, MD, Sung-Won Kim, MD, Dai Maruyama, MD, Shin-ichiro Mori, MD, Takashi Watanabe, MD, Ryuji Tanosaki, MD, Kinuko Tajima, PHD, Kensei Tobinai, MD, Yoichi Takaue, MD

Blood (2007) 110 (11): 5055.

https://doi.org/10.1182/blood.V110.11.5055.5055

Published: 2007

Journal Articles

Reduced Intensity Conditioning (RIC) with Cladribine, Busulfan and 4 Gy Total Body Irradiation (TBI) for Bone Marrow Transplantation (BMT) from an HLA-Matched Unrelated Donor (URD): A Prospective Multi-Institutional Clinical Trial.

Blood (2006) 108 (11): 5397.

https://doi.org/10.1182/blood.V108.11.5397.5397

Published: 2006

Journal Articles

Evaluation of Pre-Transplantation T-Cell Receptor Excision Circles (TREC) in Reduced-Intensity Stem Cell Transplantation (RIST) Recipients.

Yuriko Morita-Hoshi, Yuji Heike, Shizuka Yamagata, Kinuko Tajima, Shuichi Taniguchi, Kensei Tobinai, Yoichi Takaue

Blood (2006) 108 (11): 2905.

https://doi.org/10.1182/blood.V108.11.2905.2905

Published: 2006

Journal Articles

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan

Blood (2006) 108 (1): 382–389.

https://doi.org/10.1182/blood-2005-02-0596

Published: 2006

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting.

Ruri Kato, MD, Takahiro Fukuda, MD, Eiji Usui, MD, Satoshi Yamasaki, MD, Dai Maruyama, MD, Yuriko Morita, MD, Sung-Won Kim, MD, Shin-ichiro Mori, MD, Ryuji Tanosaki, MD, Kinuko Tajima, PhD, Yuji Heike, MD, Atsushi Makimoto, MD, Kensei Tobinai, MD, Yoichi Takaue, MD

Blood (2005) 106 (11): 2731.

https://doi.org/10.1182/blood.V106.11.2731.2731

Published: 2005

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies Not in Remission: The Anti-Tumor Effect of Reduced-Intensity Conditioning Is Comparable to That of Conventional Myeloablative Conditioning.

Dai Maruyama, MD, Takahiro Fukuda, MD, Ruri Kato, MD, Satoshi Yamasaki, MD, Eiji Usui, MD, Yuriko Morita, MD, Sung-Won Kim, MD, Shin-ichiro Mori, MD, Ryuji Tanosaki, MD, Kinuko Tajima, PhD, Yuji Heike, MD, Atsushi Makimoto, MD, Kensei Tobinai, MD, Yoichi Takaue, MD

Blood (2005) 106 (11): 1142.

https://doi.org/10.1182/blood.V106.11.1142.1142

Published: 2005

Journal Articles

Graft-Versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.

Eiji Usui, MD, Takahiro Fukuda, MD, Ruri Kato, MD, Satoshi Yamasaki, MD, Dai Maruyama, MD, Yuriko Morita, MD, Sung-Won Kim, MD, Shin-ichiro Mori, MD, Ryuji Tanosaki, MD, Kinuko Tajima, PhD, Yuji Heike, MD, Atsushi Makimoto, MD, Kensei Tobinai, MD, Yoichi Takaue, MD

Blood (2005) 106 (11): 2015.

https://doi.org/10.1182/blood.V106.11.2015.2015

Published: 2005

NARROW

Impact of the Double Expression of MYC and BCL2 on Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma Following R-CHOP Chemoimmunotherapy

Secondary Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era

The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy

Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile

High Non-Relapse Mortality and Low Relapse Incidence in Sex-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation From Female Donor with Male Child

Alloimmune Effect May Improve Survival of De Novo Myelodysplastic Syndrome After allogeneic hematopoietic cell transplantaion: A Single Center Analysis of 115 Patients

Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC) for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan

Impact of T-Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen.

Effect of Interventions for Relapse or Progression Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience of 93 Patients.

Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients.

Reduced Intensity Conditioning (RIC) with Cladribine, Busulfan and 4 Gy Total Body Irradiation (TBI) for Bone Marrow Transplantation (BMT) from an HLA-Matched Unrelated Donor (URD): A Prospective Multi-Institutional Clinical Trial.

Evaluation of Pre-Transplantation T-Cell Receptor Excision Circles (TREC) in Reduced-Intensity Stem Cell Transplantation (RIST) Recipients.

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan

Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting.

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies Not in Remission: The Anti-Tumor Effect of Reduced-Intensity Conditioning Is Comparable to That of Conventional Myeloablative Conditioning.

Graft-Versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only